Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TLR2 | O60603 | 3/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.31 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13484350 | 0.84 | ECE1 (0.39) | LMNAHSD17B10TDP1ADRA1AEPHX2 | |
| SCHEMBL24340304 | 0.82 | MEN1 (0.44) | MEN1KMT2ASMN1; SMN2LMNATLR2 | |
| SCHEMBL29721054 | 0.82 | MEN1 (0.44) | MEN1KMT2ASMN1; SMN2LMNATLR2 | |
| SCHEMBL29240391 | 0.82 | MEN1 (0.44) | MEN1KMT2ASMN1; SMN2LMNATLR2 | |
| SCHEMBL19057218 | 0.80 | ADRA1A (0.52) | MEN1KMT2ASMN1; SMN2TLR2HSD17B10 | |
| SCHEMBL13056634 | 0.80 | ADRA1A (0.52) | MEN1KMT2ASMN1; SMN2TLR2HSD17B10 | |
| SCHEMBL18532464 | 0.80 | ADRA1A (0.52) | MEN1KMT2ASMN1; SMN2TLR2HSD17B10 | |
| SCHEMBL22690587 | 0.80 | ADRA1A (0.52) | MEN1KMT2ASMN1; SMN2TLR2HSD17B10 | |
| SCHEMBL12197743 | 0.80 | ADRA1A (0.52) | MEN1KMT2ASMN1; SMN2TLR2HSD17B10 | |
| SCHEMBL24490705 | 0.80 | ADRA1A (0.52) | MEN1KMT2ASMN1; SMN2TLR2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120276124-A1 | MAYTANSINOIDS AND THE USE OF SAID MAYTANSINOIDS TO PREPARE CONJUGATES WITH AN ANTIBODY | SANOFI (FR) | 2012-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120276124-A1 | MAYTANSINOIDS AND THE USE OF SAID MAYTANSINOIDS TO PREPARE CONJUGATES WITH AN ANTIBODY | C1R, OGFR, ARRB1 | MEN1 2870/4885KMT2A 2835/4885SMN1; SMN2 2698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.